- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| Do | OKYO Pharma Announces Chairman and Founder Acquires Shares | 185 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| Do | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 191 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 335 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
| 16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 204 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen | |
| 16.07. | Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie | 1 | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma stock surges after positive Phase 2 results for eye pain drug | 2 | Investing.com | ||
| 11.06. | Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | 417 | ACCESS Newswire | Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap... ► Artikel lesen | |
| 11.06. | OKYO Pharma to Present at the Bio International Convention | 312 | GlobeNewswire (Europe) | LONDON and NEW YORK, June 11, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 554,60 | +0,36 % | Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings | ||
| BIOXCEL THERAPEUTICS | 1,998 | +1,73 % | BioXcel reports positive correlation study results for BXCL501 | ||
| ADAPTIMMUNE THERAPEUTICS | 0,048 | -7,77 % | XFRA 473A: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILADAPTH.TH.SP.ADR6... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 4,320 | -0,74 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,156 | +1,59 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program | ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current... ► Artikel lesen | |
| CELLAVISION | 16,380 | -0,85 % | CellaVision: CellaVision appoints Monica Jönsson as Interim CFO | Monica Jönsson has been appointed Interim Chief Financial Officer (CFO) and succeeds Magnus Blixt, who has left the company as previously communicated.Monica has extensive experience from leading positions... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,300 | +1,61 % | Precision BioSciences publishes research on ARCUS gene editing platform | ||
| ZYMEWORKS | 15,500 | -1,90 % | JPM places Zymeworks on positive catalyst watch ahead of ZW191 Phase 1 data | ||
| VTV THERAPEUTICS | 17,200 | -5,49 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | • First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 13,900 | +3,73 % | Why Quoin Pharmaceuticals Is Rising In Pre-market? | ||
| NEUPHORIA THERAPEUTICS | 15,510 | 0,00 % | Morning Market Movers: ATMV, NEUP, BOF, RYOJ See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NUVATION BIO | 3,695 | 0,00 % | Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,350 | +2,27 % | Morning Market Movers: rYojbaba, Linkage Global, MIRA Pharmaceuticals, Fossil Group See Big Swings | LOWELL (dpa-AFX) - At 7:45 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,370 | -2,84 % | PLIANT THERAPEUTICS, INC. - 8-K, Current Report | ||
| ONCONETIX | 3,200 | 0,00 % | Onconetix, Inc. - S-1, General form for registration of securities |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.